Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Rationale for NTRK Testing in Patients With Cancer

Source: The Expanding Clinical Application of TRK Inhibitors in Cancer Care: A Podcast Series
In this podcast episode, join George D. Demetri, MD, and Alexander Drilon, MD, to learn why, when, and how to test for NTRK fusions in patients with diverse solid tumors.
George D. Demetri, MD
Alexander Drilon, MD
Released: October 8, 2021

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:

  • Differences between NTRK fusions vs gene mutations
  • Frequency of NTRK fusions by age and tumor type
  • When to test patients for NTRK fusions and interpreting reports
  • Methods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and liquid biopsy

Information on this Educational Activity

Faculty

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received funds for research support and consulting fees from Bayer, Ignyta, Loxo, and Roche, and serves as a member of the board of directors for Blueprint Medicines.
Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from 14ner/Elevation Oncology, AbbVie, ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, EMD Serono, Exelixis, Helsinn, Hengrui, Ignyta/Genentech/Roche, Liberum, Loxo/Bayer/Lilly, Melendi, Merus, Monopteros, MORE Health, Novartis, Nuvalent, Pfizer, Remedica, Repare RX, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Exelixis, Foundation Medicine GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and other financial support or material from Boehringer Ingelheim, Merck, Merus, and Puma.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Updated data from the CheckMate 648 study of first-line nivolumab + either chemotherapy or ipilimumab for esophageal SCC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: February 2, 2023

Stacey Stein, MD, on systemic therapy for advanced hepatocellular carcinoma, including most recent clinical data on first-line and second-line treatment options in this Clinical Care Options (CCO) text module

Stacey Stein, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: February 1, 2023 Expired: January 31, 2024

Read expert advice about the importance of managing adjuvant abemaciclib adverse events in early breast cancer, from Clinical Care Options (CCO)

Julia LaBarbera, MSN, RN, AGACNP-BC Released: January 31, 2023

Mark Pegram, MD, and Sara Tolaney, MD, MPH, discuss treatment and optimal management approaches for patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 31, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings